Neurological disorders, according to the World Health Organization, are
estimated to account for over 10% of the world’s death and disability, and it
is therefore no surprise that efforts to improve the treatment of these
disorders is on the rise. Device and biopharmaceutical companies alike are
striving to deliver improved tools in the diagnostic and treatment of these
disorders, and the materials portfolio of DSM Biomedical remains a key part of
their arsenal.
